Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• The geometric mean plasma PK parameter values indicate drug levels in participants after treatment.
• Zilovertamab vedotin was administered intravenously every three weeks to assess its pharmacokinetics.
• This phase 2 study helps evaluate the drug's effectiveness in treating metastatic solid tumors.
• Understanding these PK values may assist in optimizing treatment for patients with advanced solid tumors.